| Substance | Condition | Seq | Src | PMID | Dtl | Title |
| Hyperoside | Bladder Cancer | 1 | PM | 38464829 | 📋 | Hyperoside induces cell cycle arrest and suppresses tumorigenesis in bladder cancer through the interaction of EGFR-Ras and Fas signaling pathways |
| Hyperoside | Diabetic Nephropathy | 3 | PM | 37646382 | 📋 | Hyperoside mediates protection from diabetes kidney disease by regulating ROS-ERK signaling pathway and pyroptosis |
| Hyperoside | Diabetic Nephropathy | 1 | PM | 34925317 | 📋 | Hyperoside Suppresses Renal Inflammation by Regulating Macrophage Polarization in Mice With Type 2 Diabetes Mellitus |
| Hyperoside | Diabetic Nephropathy | 2 | PM | 33858650 | 📋 | Hyperoside ameliorates diabetic nephropathy induced by STZ via targeting the miR-499-5p/APC axis |
| Hyperoside | Kidney Cancer | 1 | PM | 24173369 | 📋 | Combination of quercetin and hyperoside has anticancer effects on renal cancer cells through inhibition of oncogenic microRNA-27a |
| Hyperoside | Kidney Stones | 1 | PM | 36942317 | 📋 | Hyperoside Ameliorates Renal Tubular Oxidative Damage and Calcium Oxalate Deposition in Rats through AMPK/Nrf2 Signaling Axis |
| Hyperoside | Nephrotoxicity | 2 | PM | 37885225 | 📋 | Hyperoside ameliorates cisplatin-induced acute kidney injury by regulating the expression and function of Oat1 |
| Hyperoside | Nephrotoxicity | 1 | PM | 36610472 | 📋 | Hyperoside attenuates Cd-induced kidney injury via inhibiting NLRP3 inflammasome activation and ROS/MAPK/NF-κB signaling pathway in vivo and in vitro |
